Cancer Immunotherapy Developer Armo BioSciences Files for Up-to-$86.25M IPO – Genetic Engineering & Biotechnology News
San Francisco Business Times |
Cancer Immunotherapy Developer Armo BioSciences Files for Up-to-$86.25M IPO
Genetic Engineering & Biotechnology News Armo BioSciences, a late-stage developer of cancer immunotherapies, will seek to raise up to $86.25 million in gross proceeds through an initial public offering, according to an S-1 registration statement filed with the U.S. Securities and Exchange … Biotechs uncork IPO plans on eve of new year |
